Navigation Links
Intarcia Therapeutics Appoints Gino Santini To Its Board Of Directors
Date:7/26/2013

nded periods of time.

Data from Intarcia's ITCA 650 Phase 2 program have demonstrated significant and sustained reductions in HbA1c and body weight over 48 weeks of treatment with a marked reduction in the GI adverse events typically associated with the self-injection products in this class. ITCA 650 is an investigational new therapy and is not currently approved by any regulatory authority. Exenatide, the active agent in ITCA 650, is a glucagon-like peptide-1 (GLP-1) receptor agonist currently marketed globally as twice-daily and once-weekly self-injection therapies for type 2 diabetes. Upon approval, ITCA 650 would represent the first injection-free GLP-1 therapy that can deliver a full year of treatment from a single minipump placement. Intarcia's robust intellectual property portfolio protects ITCA 650 through 2031.

About Intarcia Therapeutics, Inc.
Intarcia Therapeutics, Inc. is a biopharmaceutical company developing therapies to enhance treatment outcomes by optimizing and improving the efficacy, continuous administration and tolerability of drug therapies. In addition, delivering medicines just once or twice yearly virtually ensures patient adherence and compliance, which is very poor in most chronic diseases. Intarcia's drug development expertise and competitive edge are demonstrated by its abilities to stabilize proteins and peptides at above-body temperature and to deliver them in a constant and consistent manner via Intarcia's proprietary technology platform. Intarcia is pursuing a Phase 3-stage development program for type 2 diabetes and has additional programs ongoing for weight regulation to control obesity. For more information on the Company, please visit www.intarcia.com.

Intarcia and its logo are registered trademarks of Intarcia Therapeutics, Inc.


'/>"/>
SOURCE Intarcia Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Intarcia Appoints Owen Hughes Chief Business Officer and Head of Corporate Development
2. Intarcia Enrolls First Patients in "FREEDOM" Global Phase 3 Program for ITCA 650 in Type 2 Diabetes
3. Intarcia Supports American Diabetes Association Call For Independent Review Of Incretin-Based Therapies
4. Cell Therapeutics, Inc. (CTI) to Report First Quarter Financial Results on April 20
5. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing in Chelsea Therapeutics International, Ltd. to Contact the Firm
6. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
7. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
8. Zacks Industry Outlook Highlights: Eli Lilly, Forest Labs, ViroPharma, Novartis and United Therapeutics
9. Oxford BioTherapeutics Appoints Senior Industry Leader to Head its New Clinical Development Operations in Basel, Switzerland
10. Nektar Therapeutics Reports Financial Results for the First Quarter of 2012
11. Cara Therapeutics Licenses Novel Kappa Opioid Agonist, CR845, to Chong Kun Dang Pharmaceutical Corporation For South Korean Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 15, 2014  Valeant Pharmaceuticals International, Inc. (NYSE: ... waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of ... offer by its indirect wholly-owned subsidiary, Sapphire Subsidiary Corp. ... stock of Solta Medical, Inc. (NASDAQ: SLTM ...
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com ... report is available in its catalogue: ... and Technologies for Advanced Drug Delivery ... Administration http://www.reportlinker.com/p01941928/Global-Markets-and-Technologies-for-Advanced-Drug-Delivery-Systems----Focus-on-Routes-of-Administration.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_Delivery_Technology ...
(Date:1/15/2014)... Ohio , Jan. 15, 2014  A novel wearable injector ... easy and painless for patients to self-inject prescription drugs in ... disorders, including cancer, blood diseases, autoimmune deficiencies, and genetic disorders.  ... to grow to $220B by 2018, according to analysts.   Many ...
Breaking Medicine Technology:Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 16Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2
... Investment in Vaccine to Prevent Rotavirus, NEW ... that it has purchased a royalty interest in ... an oral,vaccine developed to prevent rotavirus infection, a ... infants and young children.,The product is marketed by ...
... The Public Patent,Foundation ("PUBPAT") announced today that the U.S. ... patents held by Gilead Sciences,that relate to the drug ... in the battle against HIV/AIDS. Gilead markets TDF in,the ... a part of its ATRIPLA,combination product., Roughly 40 ...
Cached Medicine Technology:Paul Capital Healthcare Purchases Additional Royalty Interest in GlaxoSmithKline's Rotarix(R) 2U.S. Patent Office Rejects Key HIV/AIDS Drug Patents at PUBPAT Request: Government Finds Prior Art Submitted By PUBPAT Invalidates All of Gilead Sciences' Claims 2
(Date:4/17/2014)... Scientists have identified new pain relief targets that ... pain. BBSRC-funded researchers at King,s College London made ... nerves in the periphery of the body. , ... and identifying mechanisms underlying pain generation and our ... related side effects." , One potential side effect ...
(Date:4/17/2014)... (April 17, 2014) Two recent papers by ... and colleagues may help scientists develop treatments or ... fever, Japanese encephalitis and other disease-causing flaviviruses. , ... and molecular genetics at the School of Medicine ... Hughes Medical Institute, and colleagues recently published articles ...
(Date:4/17/2014)... Doctors who treat patients with a severe and ... an agonizing treatment decision. , The drug sirolimus ... relieve shortness of breath. But some patients eventually ... potentially fatal complications following transplantation. , "It,s a ... director of Loyola University Medical Center,s LAM Clinic ...
(Date:4/17/2014)... School of Medicine (BUSM) have discovered that the ... experimental model. The findings, reported in the ... may lead to more effective treatments for alcoholism. ... the leading causes of illness and death in ... by limiting the productivity of workers and necessitating ...
(Date:4/17/2014)... scientists and their partners have found that their proprietary ... transmission of multiple sexually transmitted infections (STIs) in both ... virus 2 (HSV-2), and human papillomavirus (HPV). The USAID-funded ... is effective against multiple strains of HIV, and has ... three viruses of at least eight hours prior to ...
Breaking Medicine News(10 mins):Health News:New pain relief targets discovered 2Health News:CU researchers discover target for treating dengue fever 2Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3Health News:BUSM researchers find anti-seizure drug may reduce alcohol consumption 2Health News:Animal study provides first evidence that gel can prevent multiple virus transmission in vagina/rectum 2
... , SUNDAY, Dec. 26 (HealthDay News) -- How do ... living human being and not a replica such as a doll ... they are crucial to helping people distinguish real faces from those ... face and knowing that the lights are on and someone is ...
... FRIDAY, Dec. 24 (HealthDay News) -- The lack of sleep ... put their health at risk, British sleep experts suggest. ... harm Santa,s long-term health, there are short-term risks, according to ... of Warwick,s Warwick Medical School. The lack of sleep ...
... , THURSDAY, Dec. 23 (HealthDay News) -- Eating ... toxic phosphorus in the blood and urine, says a small ... intake of phosphorous -- which is found in dietary proteins ... have difficulty ridding themselves of the mineral. In these patients, ...
... activated in cancers, causes internal membranes within a healthy ... degrading proteins, preventing the enzyme from doing its job ... cell, researchers at UCLA,s Jonsson Comprehensive Cancer Center have ... enzyme, Glycogen Synthase Kinase 3 (GSK3), results in the ...
... Reporter , WEDNESDAY, Dec. 22 (HealthDay News) -- Confronting ... who are unaware they are taking dummy pills, researchers ... was fake still reported significant symptom relief. In ... (IBS), a control group received no treatment while the ...
... THURSDAY, Dec. 23 (HealthDay News) -- Liz Smith has six kids, ... of arthritis in Emily, now 18, appeared when she was just ... slipped in a swimming pool and had a swollen ankle that ... all of it." For several months, the family agonized over ...
Cached Medicine News:Health News:Could Santa's Lack of Sleep on Christmas Eve Harm His Health? 2Health News:Vegetarian Diet Cuts Kidney Patients' Levels of Toxic Phosphorus 2Health News:UCLA researchers uncover new cell biological mechanism that regulates protein stability in cells 2Health News:Placebos Work -- Even if Patients Are in on the Secret 2Health News:Placebos Work -- Even if Patients Are in on the Secret 3Health News:Lifetime of Arthritis Has Not Held Back Teen 2Health News:Lifetime of Arthritis Has Not Held Back Teen 3
The Guidant INSIGNIA Ultra pacing system offers sophisticated patient-specific, easy-to-use features for simplified patient management and enhanced patient safety....
... fast, the HI VISION 8500 diagnostic ... with user-oriented operation for exceptional imaging ... package consists of advanced techniques for ... COMPOUND multi-angle spatial compounding, wideband pulse-inversion, ...
... range of diagnosis by using the Convex Scanning ... clear image of blood flow by using the ... accessory elevator has been incorporated and the balloon ... for more advanced and accurate techniques. The FG-36UX ...
... system is an expanded menu profiler designed ... much as 50 percent and deliver faster ... the AccuSense® glucose oxygen sensor, enhanced data ... the CX9 ALX system offers general and ...
Medicine Products: